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The benefit of administering chemical thromboprophylaxis to chronic kidney disease patients undergoing renal 
transplantation is unclear and no previous systematic review has addressed this as reflected by variations in 
national guidelines.  
 
Methods 
A literature search was performed using MEDLINE, Embase, Cochrane, CINAHL, World Health Organisation 
(WHO) International Clinical Trials Registry Platform and ClinicalTrials.gov databases to December 2019.  Studies 
included participants undergoing renal transplantation only with no contra-indication to thromboprophylaxis, 
no history/clinical suspicion of acute organ rejection and those describing a form of chemical 
thromboprophylaxis intervention compared with another form, no intervention or placebo. 
 
Results 
Thirteen studies with 1600 patients were included. There was wide variation concerning type of 
thromboprophylaxis, time of onset, dosing and duration. Reports of symptomatic/asymptomatic venous 
thromboembolism and mortality were limited.  Seven studies reported on renal allograft thrombosis. When 
comparing thromboprophylaxis to no intervention, there was no evidence of difference for thrombosis risk (risk 
ratio 0.2; [95% CI 0.01 – 4.63]), however all studies were underpowered to answer this question. Six studies 
reported on major bleeding but type of intervention, timing of onset and duration of thromboprophylaxis varied 
significantly, making it difficult to pool data for further analysis.  
 
Conclusion 
There is insufficient evidence to advise on efficacy and safety of chemical thromboprophylaxis in patients 



























Renal transplantation is a gold standard treatment for stage 5 chronic kidney disease (CKD) -  
defined as reduction of glomerular filtration rate (GFR) to 15ml/min/1.73 m2 or below, or patients receiving 
renal replacement therapy (i.e. haemodialysis or peritoneal dialysis). Data from different national registries 
show an increase in the number of transplant operations over the last decade (1-5). 
 
CKD results in altered haemostasis (increased risks of both venous/arterial thrombosis) and bleeding (6-8).  The 
increased risk of thrombosis, in particular venous thromboembolism (VTE) is thought to be due to an increase 
in both procoagulant factors as part of the chronic inflammatory process and anti-fibrinolytic proteins that 
inhibit clot breakdown (8-10). The increased risk of bleeding is due to several factors such as platelet dysfunction 
induced by uraemia, anaemia, thrombocytopenia and use of anti-platelet/anticoagulant agents during 
haemodialysis (8, 9, 11, 12). 
 
VTE, comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with significant short 
and long-term morbidity and mortality(13). For patients who undergo renal transplantation, the risk of VTE 
increases further due to surgery, patient-related risk factors (increasing age, obesity, immobility, thrombophilia, 
previous VTE etc.) and post-operative related risk factors, such as use of immunosuppressive medication (14). 
Further, these patients are also at risk of developing renal allograft vascular thrombosis (renal artery or renal 
vein) which is a major early complication post renal transplantation that often results in graft loss (7, 15, 16), 
causes of which are often attributed to surgical factors from damage to the renal vessels, twist on implantation 
or graft repositioning (17, 18).   
 
As these patients represent a unique and challenging cohort with a predisposition to both thrombosis and 
haemorrhage chemical thromboprophylaxis (TP) may increase their bleeding risk, whilst its omission may 
increase their risk of VTE and graft thrombosis.  The optimal approach to administering chemical TP during 
renal transplantation with regards to type and duration of anticoagulant that should be used is unknown (16). 
National guidelines (Table A1, appendix A) (19) on the use of chemical TP are mainly for general urology 
patients, with none of the recommendations being specific to renal transplant surgery. 
 
Given the background predisposition to both thrombosis and bleeding in patients with CKD we undertook a 
systematic review of the literature to evaluate the effectiveness and safety of different pharmacological 
thromboprophylaxis agents in patients undergoing renal transplant surgery. 
The primary objective was to assess the effectiveness and safety of a chemical TP agent (any type) with another 
form(s) of chemical TP or placebo or no intervention for preventing VTE after renal transplantation up to 3 
months post-transplant.  Secondary objectives looked at similar outcomes up to 12 months post-transplant. 
Mechanical TP strategies were not considered. 
 
Types of chemical TP included one or more of the following: low-molecular-weight heparin (LMWH), 




This review was prospectively developed, registered (PROSPERO CRD42018103137) and conducted in 
accordance with published guidelines described in the Cochrane Handbook (20).  Reporting was per the 
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Ethical approval was 





Search strategy and study selection  
Databases were searched from inception to 16 December 2019: Pubmed (electronic publications), MEDLINE 
(Ovid SP), Embase (Ovid SP), Cochrane, CINAHL (Ebsco), World Health Organisation International Clinical Trials 
Registry Platform (apps.who.int/trialsearch) and ClinicalTrials.gov (clinicaltrials.gov). There was no restriction on 
language or year of publication. Reference lists of relevant studies were also searched, where appropriate 
(Search strategy, Appendix B). 
 
All randomised trials controlled clinical trials, non-randomised studies, single and multiple intervention studies 
were considered. Systematic reviews were used to identify relevant studies. Recipients (any age and gender) 
who underwent renal transplantation (deceased/live donor) for any medical condition were included. All 
studies comparing a form of chemical TP (as listed above) to another chemical TP or no intervention or placebo 
were included. 
 
Two review authors (RK and AZ) independently assessed all studies. To be eligible, studies had to (1) include 
participants (any age) who were undergoing renal transplantation only and had no contra-indication to TP e.g.  
a bleeding disorder, (2) did not have a history of acute organ rejection or clinical suspicion of the same, and (3) 
the study compared a form of chemical TP intervention to another form or no intervention or placebo.  Studies 
were excluded if there was only a historical comparison arm because these studies are at critical risk of bias. 
 
Outcome measures 
Primary outcome measures were assessed up to 3 months post-transplant.  These included effectiveness 
measures i.e. symptomatic VTE (deep venous thrombosis [DVT] and pulmonary embolism [PE]), confirmed by 
radiological examination such as venography, ultrasonography, ventilation-perfusion scan, CT scan or 
angiography, asymptomatic VTE or renal allograft thrombosis (arterial and venous) diagnosed by radiological 
examination as described above.  Safety outcome measures included major bleeding defined as per International 
Society on Thrombosis and Haemostasis (ISTH) criteria (i.e. overt bleeding associated with a decrease in 
haemoglobin of ≥ 20g/L, transfusion of 2 or more units of blood or occurring at a critical site [intracranial, intra-
spinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, 
gastrointestinal]) (21) and mortality from major bleeding, VTE and all-cause (cardiovascular, other). 
 
Secondary outcome measures were assessed up to 12 months post renal transplant.  Clinically relevant non-
major bleeding (not meeting criteria for major bleed but still requiring intervention) was also assessed as a 
secondary outcome. 
 
Data Extraction and Quality Assessment 
Data was independently extracted using a standardised form and any disagreements were resolved by either 
consensus or discussion with a third author (LG). The review authors were not blinded to names of authors, 
institutions, journals or the study outcomes. Attempts to contact authors (Broyer (22) and Murashima (23)) 
where data was only available in abstract form was made.  No response was received from either author. 
 
For randomized controlled trials (RCTs) risk of bias was assessed using Cochrane's risk of bias assessment tool 
for included randomised controlled trials (20). Items were classified into ’low risk’, ’high risk’, or ‘unclear risk’.  
Consensus on the degree of risk of bias was through comparison of the review authors’ statements. For non-
RCTs, of bias was done using ROBINS-I tool.  The quality of evidence was rated as ’low risk’ (comparable to a 
well-performed randomized trial), ‘moderate risk’ (cannot be considered comparable to a well-performed 
randomized trial), ’serious risk’ (study has some important problems), or ‘critical risk’ (study too problematic to 




Where clinical and methodological characteristics of individual studies were sufficiently homogeneous, data 
were combined. Meta-analysis was not possible due to heterogeneity among trials. Results were presented 
narratively in tabular form. 
 
RESULTS 
Study selection and characteristics  
8682 citations were identified through database searching. After duplicate removal and screening by two 
independent authors 7032 records were excluded based on the abstract. Forty-two full text articles were 
reviewed and 13 identified as eligible (Figure 1). Of these, five were randomised trials (24-28), 1 was a non-
randomised controlled trial (22) and 7 were cohort studies (19, 23, 29-33). There were no ongoing trials. Included 
studies were published between 1974 and 2016. The total number of patients in the included studies was 1600 
(see Table A2, Appendix A). 
 
Three studies (one RCT [n = 75] and two cohort studies [n = 688] patients) compared LMWH with UFH and no 
intervention (19, 28, 29). Three studies (one controlled trial [n= 115] and two cohort studies [n = 285]) compared 
LMWH with no intervention (22, 30, 32). Four studies (two randomised trials [n = 105] and two cohort studies 
[n= 518]) compared UFH with no intervention(25, 27, 31, 33). Two randomised trials (n = 113) compared warfarin 
with no intervention (24, 26) and 1 cohort study (n=87) compared aspirin with no intervention (31). 
 
The timing of initiation of TP was reported in three randomised trials (24-26) and four non-randomised trials 
(non-RCTs) (29, 30, 32, 33). The duration of TP treatment ranged from 7-180 days. Patient follow-up varied 
between studies from 2 weeks to 48 months (in the intervention arm). 
 
A summary of the general characteristics of all included studies is provided in Table 1.  Data from two studies 
(30, 31) were not included in further analysis as follow up of the specific interventions was very different and 
























Figure 1: PRISMA study flow diagram 
 











Table 1:  General Characteristics of Included Studies 
Author Year Country Multi-centre Sample 
Size 
Intervention (Dose) Comparator (Dose) Onset of TP Duration of TP Follow-up Period 
RANDOMISED CONTROLLED TRIALS 
Osman (28) 2007 Egypt No 75 LMWH (3500iu OD) UFH (5000iu BD) 
No Intervention 





Yes (x3) 54 Warfarin (dose 
adjusted to maintain 
the prothrombin time 
between 2 to 3 times 
normal 















17 days 16 months 
Mathew  
(26) 
1974 Australia No 54 OAC (dose adjusted to 
maintain the 
prothrombin time 
between 2 to 2.5 times 
normal) + 
Dipyridamole (25mg 
QDS, increased in steps 
to 100mg QDS by end 
of week 3) 
No Intervention As soon as 
clinically 
possible - 
mean delay 17 
days 
 
NS OAC + Dipyridamole: 
Mean 33.5 months 
(no range given) 
No Intervention: 
mean 29.6 months 
















2011 Poland No 67 UFH Intra-op (2500iu 
then 10000-15000iu 
continuous infusion)  




UFH: 2 days 




2016 Canada No 547 Prophylactic heparin 
(variable doses; 5000iu 














2012 Turkey No 50 LMWH (40mg OD) No Intervention 1 day pre-op First post-op 
week 
LMWH: mean 11 
days (9-26) 
No intervention: 
mean 21 days (13-38) 
Esfandiar 
(31) 
2012 Iran No 87 UFH (50u/kg q8h) + 
ASA (5mg/kg three 
times/week) 
No Intervention NS Heparin, 7 days 
+ ASA, 3 months 
Heparin + ASA: 24 or 
48 months (unclear) 




2002 Sweden No 120 LMWH (variable doses 
and formulations; 
20mg OD, 40mg OD, 
2500iu OD, 5000iu OD) 





2005 Australia No 326 UFH (500-1000iu/hour) No Intervention Median 8 days 
(1-14) 
NS 2 weeks 
Murashima (23) 
Abstract Only 
2010 USA No 48 Heparin + warfarin Heparin + Aspirin 
Heparin 
No intervention 
NS NS NS 
TP, thromboprophylaxis; UFH, unfractionated heparin; LMWH, low molecular weight heparin; ASA, aspirin; NS, not stated; OAC, oral anticoagulant; q8h, every 8 hours; q12h, every 12 hours; OD, once a day; QDS, four times a day; BD, 




All RCTs were assessed to be at high risk of bias (Figure 2). Risk of bias assessment, addressing renal allograft 
thrombosis and major bleeding was also done for cohort studies using the ROBINS-I tool.  All except for two 
studies 29,30 (where data was only available in abstract form) were assessed as serious risk (Figure A1, Appendix 
A). 
 














































    
 
   
Osman (2007) 
 
   
 
   
Judgement: High; Unclear;  Low 
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Primary outcomes (up to 3 months) 
Effectiveness 
Because of different TP agents and comparators, analysis of outcomes has been presented separately for 
studies comparing a single chemical TP agent versus no intervention/placebo (or active treatment versus no 
intervention) and a single chemical TP agent versus one/more other interventions (or active treatment versus 
another treatment). 
 
Venous thromboembolism (VTE) 
Active treatment versus no treatment 
Symptomatic VTE 
One cohort study (Table 2) reported on symptomatic VTE and this was a single centre retrospective study 
comparing UFH (n=10) with no intervention (n=310). No patients developed symptomatic VTE in the UFH arm; 
the number developing VTE in the no treatment arm was not reported. Follow-up was short at 2 weeks (33).  
 
Asymptomatic VTE 
No study reported on this outcome. 
 
Active treatment versus another treatment 
Symptomatic VTE 
No study reported on this outcome. 
 
Asymptomatic VTE 
One RCT (28) comparing UFH (n=25) or LMWH (n= 25) with no treatment (n=25) reported no cases of VTE in 
any intervention arm (Table 2). Details of how this outcome was assessed radiologically were not specifically 
stated. Follow-up was 2 weeks. 
 
Table 2: Number of participants with VTE 
ACTIVE TREATMENT VERSUS NO TREATMENT† 
Symptomatic VTE 
Author/Year Intervention Type 
(n) 






 No Rx (310) NS 2 weeks ⊕⊖⊖⊖ 
Very Low 
 
UFH (16) then 
LMWH (10) 
0 
ACTIVE TREATMENT VERSUS ANOTHER TREATMENT* 
Asymptomatic VTE 
Author/Year Intervention Type 
(n) 





No Rx (25) 0 2 weeks ⊕⊖⊖⊖ 
Very Low 
 
LMWH (25) 0 
UFH (25) 0 
VTE, venous thromboembolism; UFH, unfractionated heparin; Rx, treatment; LMWH, low molecular weight heparin; NS, not stated 
* Symptomatic VTE not reported by any study in this category 
 † Asymptomatic VTE not reported by any study in this category 
 
^ GRADE Working Group grades of evidence used to assess certainty of evidence for all outcome measures (35): 
High certainty:  We are very confident that the true effect lies close to that of the estimate of the effect 
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Moderate certainty:  We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of 
the effect, but there is a possibility that it is substantially different 
Low certainty:  Our confidence in the effect estimate is limited: The true effect may be substantially different from the 
estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different 
from the estimate of effect 
 
Renal allograft thrombosis 
Seven studies (two RCTs (27, 28), 1 controlled trial (22) and 4 cohort studies (23, 29, 32, 33)) reported on the 
proportion of participants who developed renal allograft thrombosis (Table 3).  Only one cohort study (29) did 
not report the outcome per intervention arm. 
 
Active treatment versus no treatment 
In the controlled trial(22), there were higher numbers of renal allograft thromboses in the no treatment arm 
(12.3%) compared to the treatment arm (LMWH) (2.1%). The length of follow-up was not described.  
 
Three cohort studies reported the number of participants developing renal allograft thrombosis per treatment 
arm; only two studies reported similar follow-up times for both study arms(32, 33).  None of the studies 
adjusted the results to account for confounding factors (Table 3).  
 
Three trials (25, 27, 28) (one (25) which reported outcomes beyond 3 months, see Table A3, Appendix A) 
comparing UFH with no intervention showed no evidence of a difference for thrombosis risk between the arms 
(risk ratio 0.2; [95% CI 0.01 – 4.63]). However, all three studies were small with a high risk of bias.  Meta-
analysis was not possible for this outcome as the patient follow up periods were very different. 
 
Only two studies compared a TP versus another TP treatment, both were of small size (Table 3) reporting very 
low rates of renal artery thrombosis within 2 weeks.    
 
Table 3: Renal Allograft Thrombosis 
 Author/Year Intervention 











ACTIVE TREATMENT VERSUS NO TREATMENT 
RCT 
Ubhi 1989 (27) UFH (32) 5000iu  0 30 days ⊕⊖⊖⊖ 
Very Low 
 
No Rx (37) N/A 2 (5.4%) 
Controlled Trial 
Broyer 1991 (22) 
 
LMWH (47) NS 1 (2.1%) NS Unclear 
No Rx (73) N/A 9 (12.3%) 
Cohort Studies 
Kusyk 2005  
(33) 
UFH (16) 500-1000iu/hr 0 2 weeks ⊕⊖⊖⊖ 
Very Low 
 
No Rx (310) N/A 3 (0.9%) 
 
Lundin 2002  
(32) 
LMWH (56) Variable: 20mg 
OD, 40mg OD, 
2500iu OD, 
5000iu OD 
0 47 days ⊕⊖⊖⊖ 
Very Low 
 












NS 1 (6.3%) NS Unclear 
No Rx (32)  6 (18.8%) 





No Rx (25) N/A 0 2 weeks ⊕⊖⊖⊖ 
Very Low 
 
LMWH (25) 3500iu OD 0 
UFH (25) 5000iu BD 0 
Cohort Studies 
Pawlicki 2011  
(29) 
UFH intra-op 




1* (1.5%) 14 days ⊕⊖⊖⊖ 
Very Low 
 
LMWH (8) NS 
No Rx (48)  
RCT, randomised controlled trial; ASA, aspirin; UFH, unfractionated heparin; Rx, treatment; SC, sub-cutaneous; LMWH, low molecular 
weight heparin; APT, anti-platelet therapy; OAC, oral anticoagulant; NS, not stated; N/A, not applicable; q8h, every 8 hours; q12h, 
every 12 hours; OD, once a day; QDS, four times a day 
 
Safety – Major Bleeding 
Six studies, 1 RCT (28) and 5 cohort studies (19, 23, 29, 32, 33), reported the number of participants with major 
bleeding as per ISTH criteria (21).  See Table 4. 
 
Active treatment versus no treatment  
All 3 cohort studies (23, 32, 33) reported higher bleeding rates in the intervention arms.  However, each study 
used a different form of intervention, different timing of onset and different duration of treatment (where 
stated).  Only 1 (32) reported on resultant graft loss because of bleeding. 
 
Active treatment versus another treatment 
Three studies (1 RCT and 2 cohort studies) compared LMWH with UFH. The RCT reported a 4% major bleeding 
rate in the LMWH arm (n = 25) and no major bleeding event in the UFH arm (n = 25) (28).  Of the two cohort 
studies, one reported a bleeding rate of 3% (8/266) in participants who received prophylactic heparin and 46% 
(6/13) in those who received treatment doses of heparin (19). The second study reported a 63.6% (7/11) rate 
for the UFH arm (2500iu given intra-op then 10000-15000iu continuous infusion for 2 days) and 50% (4/8) for 
LMWH (dose not stated) (29). 
 




























UFH (16) 10 (62.5%) NS 2 weeks ⊕⊖⊖⊖ 
Very Low 
 
No Rx (310) 11 (3.5%) NS 
 
Lundin (2002)  
(32) 
LMWH (56) 4 (7.1%) 0 47 days ⊕⊖⊖⊖ 
Very Low 
 










5 (31.3%) NS NS Unclear 
 
No Rx (32) 2 (6.3%) 
ACTIVE TREATMENT VERSUS ANOTHER TREATMENT 
RCT 
Osman (2007)  
(28) 
No Rx (25) 0 N/A 2 weeks ⊕⊖⊖⊖ 
Very Low 
 
LMWH (25) 1 (4%) 0 
UFH (25) 0 N/A 
Cohort Studies 
Ng (2016) (19) 
 














7 (63.6%) 1 (9%) 14 days ⊕⊖⊖⊖ 
Very Low 
 
LMWH (8) 4 (50%) 1 (1.8%) 
(NS if 
prophylactic 
heparin or no 
Rx) 
No Rx (48) 6 (12.5%) 
RCT, randomised controlled trial; UFH, unfractionated heparin; Rx, treatment; LMWH, low molecular weight heparin; NS, not stated; 
N/A, not applicable 
 
Mortality  
Of the two cohort studies (19, 29), which reported on mortality rate, only one, described this per intervention 






Table 5: Mortality 
Studies Intervention type 
(n) 
Mortality Follow-Up Period Certainty of 
evidence 
(GRADE^) 




UFH intra-op then 




 LMWH (8) 0 
None (48) 0 
 
Ng (2016)  (19) 
None (268) 






Rx Heparin (13) 
RCT, randomised controlled trial; UFH, unfractionated heparin; Rx, treatment; LMWH, low molecular weight heparin; NS, not stated 
 
Secondary outcomes (up to 12 months) 
Due to the low number of studies reporting on the efficacy and safety outcomes beyond 3 months, and 
heterogeneity between studies in the intervention types, duration of TP and follow up period, conclusions on 




Bleeding and thrombosis are outcomes that are critical to the success of renal transplant surgery.  Current 
national and international guidelines on post-operative thromboprophylaxis are aimed at patients undergoing 
general urological procedures and do not specifically address the additional challenges of renal transplantation.  
Our systematic review, which is the first in the literature, revealed that the evidence base for making 
recommendations on thromboprophylaxis after renal transplant surgery is very poor. 
 
Main Findings 
In this systematic review, we identified 13 studies (5 RCTs, 1 controlled trial and 7 cohort studies) to assess the 
efficacy and safety of a chemical thromboprophylaxis strategy for VTE prevention post renal transplant surgery. 
 
Overall, the rate of symptomatic and asymptomatic VTE for both comparisons (i.e. thromboprophylaxis versus 
no thromboprophylaxis, and versus another active treatment) were poorly reported, and of those studies 
where this was reported, there was no evidence that thromboprophylaxis versus no treatment, or another 
thromboprophylaxis treatment, reduces VTE risk. It is important to note that the sample sizes of studies that 
did report on VTE rates were small and underpowered to answer this question. Although more studies 
reported on the rates of renal allograft thrombosis, due to heterogeneity of studies and different timing of 
follow up, we were unable to perform a meta-analysis. For both primary and secondary efficacy outcomes, due 
to the limited number of studies, we were not able to establish if one chemical thromboprophylaxis is better 
than another thromboprophylaxis. 
 
The definition of major bleeding varied between studies with only six fulfilling the ISTH criteria. Of the studies 
that compared active treatment versus no treatment, 2 RCTs (whose follow up was beyond 3 months) comparing 
LMWH and UFH versus no intervention reported higher numbers of major bleeding events in the TP arm (UFH 
22.2%, and LMWH 4%) compared to no intervention where no major bleeding was reported. However, both 
trials were small, had different follow-up periods and used different TP doses. For active treatment versus 
15 
 
another treatment comparison, only 3 reported on major bleeding of which only one was an RCT and this was 
underpowered to answer this question. 
 
Completeness, Applicability and Quality of Evidence 
None of the studies reported losses to follow-up and it is assumed there were no missing outcomes.  A few 
studies had long follow-up durations and it is questionable if the outcomes in these were attributable to the 
intervention. 
None of the studies included in this review were powered to answer the efficacy or safety outcomes of TP 
against either another TP, no intervention or placebo. The poor quality of the evidence rated as low to very 
low for all RCTs means that the results for outcomes assessed in this review cannot be applied to clinical 
settings.  
 
The RCTs included in this review were primarily single site, with a small sample size and lacked blinding of 
participants and personnel.  As a result, the quality of evidence (using the GRADE system) for the RCTS was 
rated as low to very low.  All were judged using Cochrane risk of bias assessment as high risk. 
 
Strengths and Limitations  
To our knowledge, there are no other published systematic reviews describing the efficacy and safety of different 
chemical thromboprophylaxis strategies in patients undergoing renal transplantation surgery.  A recent review 
on prophylaxis of pulmonary embolism in renal transplant patients (36) similarly concludes a lack of evidence to 
determine effective prophylactic strategies in this population.  However, there are notable differences between 
these two reviews. We have conducted a systematic review rather than a literature review, our review question 
is more specific and assesses efficacy (incidence of both symptomatic and asymptomatic VTE including renal 
allograft thrombosis) and safety (bleeding and mortality) and we have assessed the risk of bias of individual 
studies and overall quality of evidence. 
 
The RCTs had small sample sizes (all less than 100 patients). To answer our objectives, we grouped studies into 
two wide groups (active treatment versus another treatment and active treatment versus no treatment). 
However, we recognise that within these groups there is heterogeneity with regards to type of TP, dosing, 
duration and outcome measures.  Further, unpublished or non-indexed studies within the grey literature were 
not searched for, so there is a risk of missing data. 
 
We excluded a number of cohort studies from analysis as intervention arms were compared with historical non-
intervention arms.  Much has changed in terms of surgical expertise during transplant surgery, 
immunosuppressive regimens used post-transplant, VTE assessment and monitoring, and post-operative care 
(e.g. recommendation for earlier mobilisation), and we felt that reported changes in outcomes could not be 
solely attributed to introduction of the intervention. 
 
CONCLUSION 
There is a lack of good quality evidence to determine whether chemical thromboprophylaxis is efficacious and 
safe post-renal transplantation surgery. Compared to no thromboprophylaxis, there was some evidence that 
thromboprophylaxis may reduce the rate of renal allograft thrombosis, but this may be associated with 
increased risk of bleeding. However, these conclusions must be interpreted with caution due to heterogeneity 
in study design, type, and onset/duration of thromboprophylaxis between studies, highlighting the need for 
future large-scale randomised controlled trials to determine the risk benefit ratio of the various 
thromboprophylaxis options in renal transplantation surgery.  
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